Concordance of centrally performed PD-L1 assays in unresectable or metastatic gastric cancer patients treated with nivolumab plus chemotherapy (KINGCA Week 2026) - Oct 11, 2026 - Abstract #PE-047; "These findings suggest that CPS assessed using the 28-8 pharmDx assay is analytically comparable to"
Clinical • Discordant • IO biomarker • IO Companion diagnostic • Metastases • PD(L)-1 companion diagnostic • Gastric Cancer • Oncology • Solid Tumor • PD-L1
|
|
Yoonjin Kwak1; Hyeon-Su Im2; Tae-Yong Kim3; Hye Seung Lee1; Hee Jeong Cha4; Hyeon Jeong Oh5; Keun-Wook Lee6; Hee Kyung Kim7; Jina Yun8; Seung Myoung Son9; Hye Sook Han10; Hyeong Chan Shin11; Jin Young Kim12; Hye Seung Han13; Kyunghye Bang14
|